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Objectives: To estimate the 3-year budget impact of phased RF ablation system 
composed of three catheters -PVAC, MASC, MAAC- for the treatment of sympto-
matic, drug-refractory paroxysmal or persistent AF (PAF or CAF) patients in the 
Turkish setting. MethOds: Payer perspective is applied. Only direct costs are con-
sidered. Literature research is performed for epidemiologic data. Comparators are 
identified as “catheter ablation” technologies in the positive list: (1) magnetic (2) 
electric censored 3D-mapping catheter ablation, (3) pulmonary vein balloon cryo-
ablation (Medtronic ArcticFront). Device and procedure costs are derived from 
positive list prices For PVAC, MASC and MAAC offer prices are taken. Complication, 
re-hospitalization rates and length-of-stay are similar, thus related costs are 
ignored. AF-related-stroke costs are calculated based on comparative single-pro-
cedure success data, AF-related-stroke risk, and AF-related-stroke costs from a local 
expert panel. Market shares are derived from Medtronic sales data (May 2014-May 
2015) for cryo-ablation and AF market data. Two scenarios are run: (1) PVAC-only 
for PAF+CAF population, (2) MASC+MAAC combined with PVAC and/or ArcticFront 
for CAF-only. Results: Total AF population prediction is based on 50+ population. 
Prevalence data is derived from several global studies. The indicated population 
for catheter ablation is around 5,500 patients annually, the total catheter ablation 
market size corresponding to one-fourth of it; mainly due to insufficient number of 
accredited centers and physicians. 3-year budget impact per patient is 270TL, 276TL 
and 334TL in first and 268TL, 274TL and 334TL in second scenario. cOnclusiOns: 
If the limitations in quality-of-life, general health and related indirect costs are con-
sidered, the socioeconomic burden of disease would be significantly high. Indirect, 
long-term savings provided by significant shortening of procedure times with new 
technology are not included in the analysis, due to payer perspective. Considering 
these indirect costs and savings, the budget impact of new phased RF ablation 
system would be more positive.
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Objectives: To estimate the economic impact of the introduction of budesonide/
formoterol fixed-dose combination (FDC) with a new inhaler, Spiromax®, focusing 
on an increment of medication compliance due to an enhancement of the inhala-
tion technique for the treatment of Chronic Obstructive Pulmonary Disease (COPD) 
patients in five Spanish regions including Andalusia, Catalonia, Galicia, Madrid and 
Valencia. MethOds: A 4-year budget impact model was developed for the period 
2015─2018 for patients with COPD from the Spanish Healthcare System perspective. 
Budesonide/formoterol FDCs delivered by Turbuhaler® and Spiromax® inhalers 
were considered. All inputs were obtained from the published literature: regional 
data on COPD prevalence, non-compliance rates due to a poor inhaler technique, 
healthcare utilization related to non-compliance, medical resources associated with 
COPD management, budesonide/formoterol adverse event rates, and resource uti-
lization during hospitalization and at the emergency room. Based on the unit costs 
for drugs and medical resources, the annual treatment costs per patient associated 
to each inhaler and the annual cost per patient with an improvement in compliance 
were determined to estimate the overall budget impact. Results: The population 
with moderate to severe COPD treated with budesonide/formoterol FDCs in 2015 was 
estimated at 19,514, 20,016, 7,778, 21,289 and 9,936 patients in Andalusia, Catalonia, 
Galicia, Madrid and Valencia, respectively. Annual mean cost per patient was € 1,384 
before the introduction of Spiromax® and € 1,242 after its introduction and due to 
an improvement in medication compliance. Based on the forecast uptake of bude-
sonide/formoterol FDC delivered by Spiromax®, the model estimated the budget 
savings at € 2.34 million in Andalusia, € 2.23 millions in Catalonia, € 0.87 millions in 
Galicia, € 2.23 million in Madrid and € 0.77 million in Valencia, over the next four 
years. cOnclusiOns: The introduction of budesonide/formoterol FDC delivered 
by Spiromax® for the treatment of moderate and severe COPD patients is likely to 
represent savings for all five regions.
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Objectives: Heart failure (HF) is a very complex condition, with a wide range of 
unspecific clinical symptoms rendering its diagnosis very challenging, and associ-
ated co-morbidities contributing to increased expenditures. N-terminal pro-B-type 
natriuretic peptide (NTproBNP) levels increase in the blood when, in the course of 
developing acute HF, symptoms worsen. Therefore, NT-proBNP can be used as a spe-
cific diagnostic test of acute HF, whereas in patients with dyspnea it can further help 
to assess prognosis. The objective of the present study was to perform a cost and 
budget impact analysis of NT-proBNP testing. MethOds: A decision-analytic model 
formed the basis of the analysis. The model estimated the clinical consequences and 
outcomes and subsequent costs for patients presenting to the emergency department 
with dyspnea. Two diagnostic assessments were compared, NT-proBNP-supported 
diagnosis versus standard of care. The potential cost reduction, deriving from ade-
quate diagnosis and prognosis/monitoring, as well as the operating reductions (i.e 
hospitalizations) generated by NT-proBNP implementation were estimated. Clinical 
inputs derived from published literature and an expert panel provided insights into 
included in the study were with the mean age of 57 ± 14 of which 66.5% were male 
and 60.8% of the patients suffered from diabetes being a major cause for ESRD. 
Patients with age > 45, higher prevalence of diabetes, IDH, troponin T and other 
infection showed P value of 0.013, 0.002, 0.02, 0.05, 0.016 respectively, therefore 
predisposing these patient population at higher risk for SCD. Use of central venous 
catheter was associated with a 26.9 fold increase risk of death within first 90 days 
of initiation of HD. cOnclusiOns: Our study showed, type of vascular access for 
HD procedure, age, IHD, diabetes, LVH, LVSD, and EF are important factors for the 
survival of these patients and off the other factors found significantly associated to 
SCD were heart rate, breathlessness, other infections, catheter use, sodium levels 
and cholesterol levels.
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Objectives: Circulating tumour cells (CTCs) in the blood can give important infor-
mation about the prognosis and treatment options for cancer patients. Methods 
like cell-search are not sensitive enough because the blood samples are small (7,5 
mL). Currently a technique is developed which can separate CTCs from the whole 
blood and is called the CTC Trap. This study addresses the potential impact of imple-
menting the CTC Trap in addition to currently used imaging techniques in early 
staging of primary stage I-III breast cancer in women. MethOds: The early staging 
process has been identified using the Dutch breast cancer guideline. This process is 
displayed in a decision tree. Three points in this process have been identified as pos-
sible implementation options for the CTC Trap. A simulation model has been built 
in Excel to simulate the cost-effectiveness of implementing the CTC Trap at these 
three different points. Results: Potentially relevant points for the CTC trap are: 
1) following negative sentinel lymph node procedure to test for micro metastases, 
2) following negative result of initial MRI to test for (micro-) metastases, 3) follow-
ing negative results of further imaging. Usual care resulted in an average survival 
of 2,42 years, a 3-year survival of 93,71%, 1,51 QALYs and a cost of € 992,56. When 
implemented at all 3 implementation points simultaneously CTC Trap resulted in 
an average survival of 2,84 years, a 3-year survival of 97,46 %, 1,84 QALYS and a total 
cost of € 6.035,45. cOnclusiOns: CTCs clearly have the potential to improve overall 
survival. Use of CTCs can potentially improve survival with 0,42 years and improve 
QALYs with 0,34. Costs do increase at all options but from a health economic per-
spective it is most valuable to implement CTC Trap in option 1) following negative 
sentinel lymph node procedure to test for (micro-) metastases.
MEDical DEvicE/Diagnostics – cost studies
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Objectives: To assess the economic impact of the introduction of budesonide/
formoterol fixed-dose combination (FDC) with a new inhaler, Spiromax®, focusing 
on an increment of medication compliance due to an enhancement of the inhala-
tion technique for the treatment of moderate to severe asthmatics in five Spanish 
regions including Andalusia, Catalonia, Galicia, Madrid and Valencia. MethOds: 
A 4-year budget impact model was developed for the period 2015─2018 from the 
Spanish Healthcare System perspective. Budesonide/formoterol FDCs delivered 
by Turbuhaler® and Spiromax® were considered in this model. All inputs were 
obtained from the literature: regional data on asthma prevalence, non-compliance 
rates due to a poor inhaler technique, healthcare utilization related to non-com-
pliance, medical resources associated with asthma management, budesonide/for-
moterol adverse event rates, and resource utilization during hospitalization and 
at the emergency room. Based on the unit costs for drugs and medical resources, 
the annual treatment costs per patient associated to each inhaler and the annual 
cost per patient with an improvement in compliance were determined to estimate 
the overall budget impact. Results: The population with moderate to severe 
asthma treated with budesonide/formoterol FDCs in 2015 was estimated at 25,081, 
12,392, 16,097, 17,829 and 15,148 patients in Andalusia, Catalonia, Galicia, Madrid 
and Valencia, respectively. Annual mean cost per patient was estimated at € 1,619 
before the introduction of Spiromax®, and at € 1,481 after its introduction and due to 
an improvement in medication compliance. Based on the forecast uptake of bude-
sonide/formoterol FDC delivered by Spiromax®, the model estimated the budget 
savings at € 2.92 million in Andalusia, € 1.35 million in Catalonia, € 1.79 million in 
Galicia, € 1.83 million in Madrid and 1.30 € million in Valencia, over the next four 
years. cOnclusiOns: The introduction of budesonide/formoterol FDC delivered 
by Spiromax® for the treatment of moderate to severe asthma is likely to reduce 
the healthcare budget for five Spanish regions.
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Objectives: To compare both economic and clinical impact of alternative cer-
vical cancer (CC) screening strategies for women 25-65 years old using different 
algorithms with primary screening methods including cytology alone or hrHPV 
test and genotyping. MethOds: Screening and diagnosis of CC were modeled by 
a decision tree while the natural history of the disease was simulated by a Markov 
model using published available data. The compared strategies were: 1) trienni-
ally hrHPV testing with 16/18 genotyping and reflex cytology 2) triennially HPV 
testing with reflex genotyping and reflex cytology and 3) annually cytology alone. 
Clinical inputs were derived from the HERMES local trial. Unit costs for the resources 
used were obtained from the official price lists while the HPV test cost was based 
on the private’s sector prices. In the absence of relevant data, the cost of treat-
ing cervical intraepithelial neoplasia (CIN2+) and invasive CC was based on the 
respective Spanish costs which were converted to 2014 Greek values using the rel-
evant Consumer Price Index and Purchasing Power Parity exchange rate. Results: 
Strategy 1 was proved to be the dominant option as it was estimated to be less costly 
and more effective. In more detail, cytology alone detected 58% and 52% of CC and 
CIN2+ cases, respectively while strategies 1 and 2 managed to detect 94% and 85% 
of CC and CIN2+cases,respectively. In terms, of CCs missed, strategy 3 appears to 
miss 24 incidents annually in contrast to 18 of strategies 1 and 2. The annual cost 
of strategy 1 was estimated at € 14,568,412 compared to the cost of strategy 2 and 3 
which was estimated at € 38,109,522 and € 18,209,511, respectively. cOnclusiOns: 
The adoption of hrHPV test with 16/18 genotyping as a primary screening method 
can generate significant savings to the Greek health care system and in parallel 
optimize health outcomes.
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Objectives: Our objective was to study the economic impact of the four main 
endovascular treatment strategies for femoropopliteal arterial disease on payers 
in the German healthcare system, using up-to-date clinical evidence and current 
reimbursement amounts. MethOds: We estimated latest clinical performance of 
percutaneous transluminal angioplasty (PTA), bare metal stents (BMS), drug-coated 
balloons (DCB), and drug-eluting stents (DES) by performing a systematic search for 
studies published through 2014 that reported target lesion revascularization (TLR) 
as an endpoint. 24-month TLR rates were estimated for each treatment weighted 
by sample size. We updated a previously published decision-analytic Markov model 
to assess budget impact to payers of the four index procedure strategies using 
2015 reimbursement rates for Germany and considering up to one reinterven-
tion. Results: Twenty-nine studies were included. Pooled 24-month probabilities 
of TLR were 16.5%, 19.4%, 26.9%, and 39.6% for DCB, DES, BMS, and PTA, respectively. 
Over 24 months, DES had the lowest budget impact to payers of € 3,799, closely fol-
lowed by DCB (€ 3,913). The corresponding amounts for BMS and PTA were € 4,189 
and € 4,451, respectively. Comparing the most effective (DCB) to the least effective 
therapy (PTA), we found a number needed to treat (NNT) of 4.34. This suggests that 
for every four patients treated with DCB as opposed to PTA, one TLR could be avoided 
over 24 months, at overall cost savings to the healthcare system. cOnclusiOns: 
Latest clinical evidence suggests that drug-coated balloons provide the most favora-
ble clinical outcome among the considered endovascular treatments for femoro-
popliteal artery disease. Our updated economic analysis finds DES and DCB to also 
be associated with lowest cost to payers in the German healthcare system, closely 
followed by drug-eluting stents. These results, based on larger evidence base, con-
firm earlier findings.
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Objectives: IBS is considered a diagnosis of exclusion based on several labo-
ratory and diagnostics procedures to exclude other organic conditions. A novel 
IBS diagnostic blood panel has been developed which tests for the presence of 
two biomarkers associated with IBS-D. This analysis estimates the cost impact 
to the Italian healthcare system by introducing this test into the diagnostic 
pathway. MethOds: A budget impact model was based on a cost-minimization 
decision model developed to compare the costs associated with two possible 
diagnostic pathways: (1) diagnostic pathway with a novel IBS diagnostic blood 
panel and (2) exclusionary diagnostic pathway and applied to the Italian popula-
tion 18-65yrs old. Model structure was based on current literature and guidance 
from IBS expert clinicians. Direct medical expenses for laboratory tests, diagnostic 
procedures and visit costs were included in Euros and weighted by utilization 
rates provided by practicing gastroenterologists in Italy. Indirect cost estimate 
was based on the literature and only included time off work, adjusted for per 
capita income in Italy. Results: Colonoscopy, ultrasound and SBFT were the most 
common diagnostic (instrumental) procedures reported with estimated utilization 
rates of 50%, 90% and 35%, respectively. Corresponding charges were € 312.50, € 70 
and € 300, respectively. Estimated total base case charges for the IBS diagnostic 
panel pathway (assumes 75% of test positive patients receive IBS-D treatment) 
vs the exclusionary pathway were € 1,351 vs € 1,425, respectively. If clinicians use 
the test 50% of the time for the 50% of the estimated 447,275 people who might 
have IBS-D who seek treatment, net savings to the Italian healthcare system is 
€ 27,581,982. Cost neutrality occurs if 49% of the “test positive” patients seek IBS 
standard care. Related costs were calculated according to Greek NHS official prices. 
The analysis was undertaken from a Greek third-party payer perspective. Results: 
According to the model, the reduction in expenditures related to diagnosis and prog-
nosis/monitoring with NT-proBNP use were estimated at € 6.8 and € 3.2 million/year 
respectively. The projected net savings, considering the cost of NT-proBNP implemen-
tation (€ 718,000), were calculated at € 9.3 million. NT-proBNP testing also generated 
reduced use of health care resources, by preventing 1,890 initial hospitalizations/year, 
leading to 10,235 fewer hospitalization days in general ward and 3,232 in intensive 
care unit, and avoiding 491 hospital readmissions/year. cOnclusiOns: The overall 
reductions in hospitalizations and length of stay, achieved by early diagnosis and 
prognosis of HF with the implementation of NT-proBNP, could generate cost-savings 
and increase hospitals’ efficiency and productivity.
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Objectives: Existing guidelines recommend determination of RAS mutation sta-
tus in patients with metastatic colorectal cancer (mCRC) as anti-epidermal growth 
factor receptor (anti-EGFR) therapies are ineffective in tumors with RAS mutations. 
The cobas® KRAS Mutation Test (cobas test) detects twelve mutations in KRAS 
exon 2 and seven mutations in exon 3, whereas the therascreen KRAS RGQ PCR 
Kit (therascreen test) detects seven overlapping mutations in KRAS exon 2. We 
estimated the potential clinical and economic impact of using the cobas test versus 
the therascreen test in all mCRC patients in Denmark. MethOds: A budget impact 
model was developed from the Danish healthcare perspective. Model inputs were 
obtained/estimated from the literature (e.g. 1,260 annual mCRC cases were esti-
mated). Treatment patterns were from Roche data on file. Sensitivity and specificity 
were assumed to be the same as positive percent agreement and negative percent 
agreement comparing to Sanger sequencing, which were 96.9% and 88.7% for cobas, 
94.2% and 87.5% for therascreen. Drug and treatment-related costs were calcu-
lated from the national pharmaceutical procurement service (Amgros) and Danish 
national tariffs, respectively. The model calculated the average treatment cost for 
mCRC patients over 5 years, using median time on treatment and median overall 
survival. Costs were presented in 2015 Euros (1 Euro = 7.46021DKK). Results: Using 
the cobas test resulted in a reduction of 63 patient-months lost due to inappropri-
ate care (avoiding anti-EGFR therapies in mutant patients) and an improvement in 
median overall survival. Using cobas KRAS testing reduced the costs of inappropri-
ate care by € 991K and decreased monthly cost per patient by € 3, while having a 
minor increase (€ 105K, 0.2%) in healthcare costs. cOnclusiOns: Using the cobas 
test with better sensitivity and broader mutation coverage of KRAS was associated 
with a neutral budget impact and may improve patient outcomes by reducing the 
likelihood of receiving inappropriate care in mCRC patients.
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Objectives: Oral Anticoagulant Therapy (OAT) with antivitamin K antagonists for 
prevention of thromboembolic and vascular events requires a frequent monitoring 
of prothrombin time and a dose adjustment to maintain the intensity of anticoagula-
tion within a safe and effective range. The objective of the study was to quantify the 
budget impact after the introduction of the decentralized monitoring model for OAT 
patients. This model creates a link between specialized hospitals and pharmacies 
in the territory using Point-of-Care coagulometer CoaguChek and the telemedicine 
system TaoWeb, guaranteeing fewer adverse events thanks to increased accessibility 
to the service, compared to the centralized monitoring model and non-specialized 
monitoring model, and an elevated standard of quality. MethOds: A comparative 
analysis was carried out on three patient management models following the prospec-
tive of NHS with a time horizon of five years, taking the following into account: phar-
maceutical treatments, patient monitoring and adverse events. The rate of adverse 
events was estimated from scientific literature and the consumption of resources 
was quantified taking into consideration the DRG tariffs and the outpatient national 
tariff list. Results: The adoption of the decentralized monitoring model compared 
to the centralized and non-specialized model leads to an annual saving of € 236.45 and 
€ 525.15, respectively. Considering a target population of 491,093 patients requiring 
OAT and the monitoring model distribution among patients is 1.7% with the decen-
tralized model, 86.4% with the centralized model and 11.9% with the non-specialized 
model. Assuming an incremental adoption rate of 6% per year of decentralized moni-
toring, the model predicted an annual cost saving of over € 43.3 million by its fifth 
year. cOnclusiOns: Despite initial higher investments for Point-of-Care coagulom-
eter and the telemedicine technology, the decentralized monitoring model for OAT 
patients allows a budgetary saving compared to centralized monitoring model and 
non-specialized monitoring model with a potential increase of patient quality of life.
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